Veradermics (MANE) Total Liabilities (2024 - 2026)

Veradermics (MANE) posted Total Liabilities of $6.7 million for Q1 2026, down 26.65% on a QoQ basis from $9.2 million in Q4 2025.

Veradermics (MANE) Total Liabilities (2024 - 2026) Analysis & Trends

Veradermics' Total Liabilities history runs 3 years deep, the most recent figure standing at $6.7 million for Q1 2026.

Quarterly Total Liabilities changed N/A year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (changed N/A YoY) and the FY2025 annual result came in at $9.2 million, up 94.07% from the prior year.
Total Liabilities was $6.7 million for Q1 2026 at Veradermics, down from $9.2 million in the prior quarter.
Across five years, Total Liabilities topped out at $9.2 million in Q4 2025 and bottomed at $4.7 million in Q4 2024.
A 3-year average of $6.9 million and a median of $6.7 million in 2026 frame the typical range for Total Liabilities.
Peak annual rise in Total Liabilities reached 94.07% in 2025, while the deepest fall reached 94.07% in 2025.
Veradermics' Total Liabilities stood at $4.7 million in 2024, then soared by 94.07% to $9.2 million in 2025, then retreated by 26.65% to $6.7 million in 2026.
Business Quant data shows MANE's Total Liabilities at $6.7 million in Q1 2026, $9.2 million in Q4 2025, and $4.7 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	60.46 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	177.22 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	3.79 Bn
4	NuCana	279.75 Bn	279.75 Bn	-	7.33 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	7.12 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	9.45 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	15.48 Mn
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.62 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	753.82 Mn
10	Veradermics	2.63 Bn	2.63 Bn	-	6.72 Mn

Download Data